- recruitingPHASE2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
This study looks at new treatments (Dostarlimab alone or with Bevacizumab) for certain gynaecological cancers that have come back or not responded to previous treatment, comparing them to standard chemotherapy. It aims to see which treatment works best.
Australia · Hong Kong · Japan - recruiting
Institut Paoli Calmettes Cervical Cancer Database
This study is gathering information from patients at Institut Paoli-Calmettes who have been diagnosed with cervical cancer. It's a way to collect and organise health details to help doctors understand the condition better in older patients.
France - recruitingPHASE1, PHASE2
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
This study is testing a new drug, UCB4594, for advanced cancers. It's the first time it’s being used in people. Researchers want to find the safest dose, understand side effects, and see if it can shrink certain tumours by helping the body's immune system.
United Kingdom - active not recruitingPHASE2
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This study looks at how a drug called tucatinib, combined with trastuzumab, works for various cancers that have a specific change (alteration) in their HER2 gene. It focuses on cancers that have spread or can't be fully removed by surgery.
United States · Belgium · Germany - recruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
United States · France · South Korea - recruitingPHASE1, PHASE2
HTL0039732 in Participants With Advanced Solid Tumours
This study is testing a new drug, HTL0039732, alone and with another cancer medicine, atezolizumab. It's for people with advanced solid tumours, aiming to see if blocking certain signals can help the immune system fight cancer. The goal is to find the right dose and see how well it works.
United Kingdom